Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mutaflor Enemas in the Treatment of Idiopathic Proctitis / Proctosigmoiditis
DRKS00000234Phase 2Completed
- Sponsor
- Ardeypharm
- Start
- Oct 2009
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of escherichia coli nissle 1917 in idiopathic proctitis, ulcerative proctitis, Ulcerative rectosigmoiditis and 1 more (4 arms), sponsored by Ardeypharm. Started Oct 2009; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
idiopathic proctitisulcerative proctitisUlcerative rectosigmoiditisproctosigmoiditis
Beyond the preview
Go deeper on DRKS00000234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000234.